Lentiviral Gene Therapy for CGD

Abstract

This is a Phase I/II clinical trial of gene therapy for treating Chronic Granulomatous Disease using a high-safety, high-efficiency, self-inactivating lentiviral vector TYF to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the TYF-CGD gene transfer clinical protocol. Phase: NA Status: RECRUITING Conditions: Chronic Granulomatous Disease Interventions: Infusion of lentiviral TYF-CGD-modified autologous stem cells

Keywords

Sources